Nutrition & Care
Q2 2022
Sales in the Nutrition & Care segment rose considerably compared with the second quarter of 2021. Both divisions contributed significantly.
|
Nutrition & Care |
Care Chemicals |
Nutrition & Health |
|---|---|---|---|
Volumes |
0.3% |
–1.4% |
4.1% |
Prices |
27.0% |
33.1% |
13.7% |
Portfolio |
–2.1% |
–2.0% |
–2.3% |
Currencies |
5.8% |
5.2% |
7.0% |
Sales |
30.9% |
34.9% |
22.3% |
Sales growth was driven by significantly higher prices across all business areas, passing on increased prices for raw materials and energy.
Currency effects, mainly relating to the U.S. dollar and the Chinese renminbi, had a positive impact on sales.
Sales development was also supported by slightly higher volumes. This was primarily due to volume growth in the Nutrition & Health division, mainly in the pharma solutions and animal nutrition businesses. The Care Chemicals division recorded slightly lower sales volumes, particularly in the oleo surfactants and fatty alcohols business, as well as in the home care, industrial and institutional cleaning and industrial formulators business.
Portfolio effects from the sale of the production site in Kankakee, Illinois, reduced sales in both divisions.
The segment’s income from operations (EBIT) before special items was considerably above the prior-year quarter. This was due to the considerable increase in EBIT before special items in the Care Chemicals division, primarily from higher margins on the back of sales growth. EBIT before special items declined in the Nutrition & Health division. Higher margins were unable to offset the increase in fixed costs resulting from scheduled turnarounds, among other factors.
|
Q2 |
H1 |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2022 |
2021 |
+/– |
2022 |
2021 |
+/– |
||||||||||||
Sales to third parties |
2,074 |
1,584 |
30.9% |
4,045 |
3,117 |
29.8% |
||||||||||||
of which Care Chemicals |
1,461 |
1,083 |
34.9% |
2,824 |
2,142 |
31.8% |
||||||||||||
Nutrition & Health |
613 |
501 |
22.3% |
1,221 |
975 |
25.2% |
||||||||||||
Income from operations before depreciation, amortization and special items |
325 |
239 |
36.1% |
676 |
555 |
21.8% |
||||||||||||
Income from operations before depreciation and amortization (EBITDA) |
322 |
295 |
9.1% |
675 |
608 |
11.1% |
||||||||||||
Depreciation and amortizationa |
113 |
101 |
11.9% |
220 |
199 |
10.7% |
||||||||||||
Income from operations (EBIT) |
209 |
194 |
7.6% |
455 |
409 |
11.3% |
||||||||||||
Special items |
–5 |
56 |
. |
–2 |
53 |
. |
||||||||||||
EBIT before special items |
213 |
138 |
54.7% |
457 |
356 |
28.4% |
||||||||||||
Assets (June 30)a |
8,169 |
6,611 |
23.6% |
8,169 |
6,611 |
23.6% |
||||||||||||
Investments including acquisitionsb |
136 |
118 |
15.0% |
243 |
218 |
11.3% |
||||||||||||
Research and development expenses |
45 |
43 |
4.0% |
85 |
83 |
2.2% |
||||||||||||
|
||||||||||||||||||